What to expect for the budget of Ukraine after the country regulates the use of hemp-based pharmacological preparations

Representatives of foreign companies that specialize in the use of the therapeutic properties of cannabis for industrial purposes or other participants in the hemp market in economically developed countries already have a reasonable question - “Why do pharmacological companies, by attracting public funds to compensate for the cost of the pharmaceuticals they create, artificially create non-competitive conditions on the market?” ...

On the pages of the specialized electronic edition of national cannabis growers, the attention of our dear readers and listeners is quite regularly focused on the mechanisms that pharmacological companies use to promote their products in a particular country. The material “ What does it mean to receive“ GW Pharmaceuticals ”Royal Prize ” in particular described the mechanism used by the British pharmaceutical company “GW Pharmaceuticals”, which provokes a situation for lobbying its own interests in the markets of countries that are interested in its leadership in terms of selling the products manufactured by the company. We have already described the mechanisms by which “ State health insurance and the sale of medical cannabis in the Czech Republic”As well as Germany. Those. after pharmacological companies lobby in their own interests certain provisions of the legislation that are of interest to them for the sale of their own products, the next stage of creating comfortable conditions for themselves in the market is lobbying for the issue related to reimbursement from the state budget of “donor countries” for the cost of pharmacological preparations manufactured on the basis of therapeutic properties of the hemp plant. 

The information published below concerns an Australian pharmaceutical company that, following the global pharmacological trend, has achieved reimbursement of the value of pharmaceutical products it sells on the Irish market, based on the therapeutic properties of cannabis, at the expense of the budget of the aforementioned island state.

Australia's MGC Pharmaceuticals has announced that its cannabis-derived epilepsy product will now be fully covered by the Health Service Executive (HSE).

“CannEpil” is a cannabidiol (CBD) drug with a small amount of tetrahydrocannabinol (THC) intended primarily for the treatment of people with refractory epilepsy, a serious condition that does not respond to conventional medications. Refractory epilepsy affects about a third of adults and up to 25% of children with epilepsy. MGC Pharmaceuticals notes that CannEpil is also indicated for various other medical conditions, including anxiety, chronic pain, PTSD and Parkinson's disease.

CannEpil is also one of three drugs currently approved for use under the Irish Medical Cannabis Access Program (MCAP) and will be available free of charge to patients under the Long Term Disease Scheme, the GMS Scheme and the Drug Payment Scheme. 

“This is a key moment for MGC Pharmaceuticals and for Irish patients who can now receive cannabis therapeutic treatments covered by National Health Insurance,” says co-founder and managing director Robie Zomer. “With the ongoing clinical trials of CannEpil, we hope that in the near future we will be able to increase the supply and availability of this drug in the most affordable way for epileptic patients around the world.”

Commentary of the specialists of the Association "Ukrainian technical hemp"

Representatives of foreign companies that specialize in the use of the therapeutic properties of cannabis for industrial purposes or other participants in the hemp market in economically developed countries already have a reasonable question - “Why do pharmaceutical companies, by attracting public funds to compensate for the cost of the pharmaceuticals they create, artificially create non-competitive conditions on the market?” ... Anticipating the prospects for the expansion of foreign pharmaceuticals based on the therapeutic properties of cannabis into the national market, does not a similar question arise for national cannabis growers who plan to work in this segment of the cannabis market.